26/04/2026
With the growing use of semaglutide in clinical practice, it is essential to proactively monitor its safety profile through strengthened pharmacovigilance activities. As its application expands to a broader and more diverse patient population, ongoing vigilance is necessary to ensure patient safety and achieve optimal therapeutic outcomes. Collaborative efforts remain central to effective signal detection, risk mitigation, and the overall strengthening of the pharmacovigilance system.
In this context, consultants are requested to closely monitor ADRs associated with semaglutide. Particular attention should be given to the careful documentation and prompt reporting of any suspected ADRs. It is also important to ensure that Individual Case Safety Reports (ICSRs) are complete, accurate, and include all relevant clinical details and patient outcomes. Your active involvement and cooperation are crucial for strengthening drug safety monitoring and protecting public health in India. All healthcare professionals are encouraged to report ADRs promptly through the Pharmacovigilance Programme of India (PvPI) reporting system.